Identifying and overcoming obstacles in angiogenic gene therapy for myocardial ischemia

Journal of Cardiovascular Pharmacology

Volumn 64, Issue 2, 2014, Pages 109-119

  Rubanyi, Gabor M ^a  

^a Cardium Therapeutics Inc   (United States)

Author keywords

angina pectoris; angiogenesis; arteriogenesis; clinical trial design; coronary collateral vessels; gene therapy

Indexed keywords

FIBROBLAST GROWTH FACTOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADENOVIRIDAE; ANGIOGENESIS; CLINICAL TRIAL (TOPIC); COLLATERAL CIRCULATION; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; HUMAN; MYOCARDIAL ISCHEMIA; PATHOPHYSIOLOGY; PROCEDURES;

ADENOVIRIDAE; CLINICAL TRIALS AS TOPIC; COLLATERAL CIRCULATION; FIBROBLAST GROWTH FACTORS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84906061894     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000107     Document Type: Review

References (91)

1. Isner JM. Angiogenesis and collateral formation. In: March KL, ed. Gene Transfer in the Cardiovascular System: Experimental Approaches and Therapeutic Implications. Boston, MA: Kluwer Academic Publishers; 1997:307-330.
2. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2012 update: A report from the American Heart Association. Circulation. 2012;125:e2-e220.
3. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2014 update. Circulation. 2014;127:e2-e222.
4. Billinger M, Kloos P, Eberli F, et al. Physiologically assessed coronary collateral flow and adverse cardiac ischemic events: A follow-up study in 403 patients with coronary artery disease. J Am Coll Cardiol. 2002;40: 1545-1550 (Pubitemid 35253630)
5. Steg PG, Kerner A, Mancini GB, et al. Impact of collateral flow to the occluded infarct-related artery on clinical outcomes in patients with recent myocardial infarction: A report from the randomized occluded artery trial (OAT). Circulation. 2010;121:2724-2730.
6. Habib GB, Heibig J, Forman SA, et al. Influence of coronary collateral vessels on myocardial infarct size in humans. Results of phase I thrombolysis in myocardial infarction (TIMI) trial. Circulation. 1991;83:739-746.
7. Hansen JF. Coronary collateral circulation: Clinical significance and influence on survival in patients with coronary artery occlusion. Am Heart J. 1989;117:290-295. (Pubitemid 19059775)
8. Meier B, Gloekler S, Zbinden R, et al. Beneficial effect of recruitable collaterals: A 10-year follow-up study in patients with stable coronary artery disease undergoing quantitative collateral measurements. Circulation. 2007;116:975-983. (Pubitemid 47329562)
9. Meier P, Hemingway H, Lansky AJ, et al. The impact of the coronary collateral circulation on mortality: A meta-analysis. Eur Heart J. 2012;33: 614-621.
10. Seiler C, Engler R, Berner L, et al. Prognostic relevance of coronary collateral function: Confounded or causal relationship? Heart. 2013;99: 1408-1414.
11. Mukherjee D, Bhatt DL, Roe MT, et al. Direct myocardial revascularization and angiogenesis-how many patients might be eligible? Am J Cardiol. 1999;84:598-600. (Pubitemid 29408596)
12. Seiler C. The human coronary collateral circulation. Eur J Clin Invest. 2010;40:465-476.
13. Rubanyi GM. Mechanistic, technical and clinical perspectives in therapeutic stimulation of coronary collateral development by angiogenic growth factors. Mol Ther. 2013;21:725-738.
14. Rissanen TT, Yla-Herttuala S. Current status of cardiovascular gene therapy. Mol Ther. 2007;15:1233-1247. (Pubitemid 46965318)
15. Gupta R, Tongers J, Losordo DW. Human studies of angiogenic gene therapy. Circ Res. 2009;105:724-736.
16. Gaffney MM, Hynes SO, Barry F, et al. Cardiovascular gene therapy: Current status and therapeutic potential. Br J Pharmacol. 2007;152:175-188. (Pubitemid 47517600)
17. Deindl E, Schaper W. The art of arteriogenesis. Cell Biochem Biophys. 2005;43:1-15. (Pubitemid 41095269)
18. Deveza L, Choi J, Yang F. Therapeutic angiogenesis for treating cardiovascular diseases. Theranostics. 2012;2:801-814.
19. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389-395. (Pubitemid 30208155)
20. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9:653-660. (Pubitemid 36749213)
21. Semenza GL. Vasculogenesis, angiogenesis and arteriogenesis: Mechanisms of blood vessel formation and remodeling. J Cell Biochem. 2007; 102:840-847. (Pubitemid 350036924)
22. Schaper W. Tangential wall stress as a molding force in the development of collateral vessels in the canine heart. Experientia. 1967;23: 595-596.
23. Carmeliet P, Jain K. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473:298-307.
24. Scheel KW, Williams SE. Hypertrophy and coronary and collateral vascularity in dogs with severe chronic anemia. Am J Physiol. 1985;249: H1031-H1037. (Pubitemid 16197346)
25. Chilian WM, Mass HJ, Williams SE, et al. Microvascular occlusions promote coronary collateral growth. Am J Physiol. 1990;258:H1103-H1111. (Pubitemid 20155554)
26. Van den Wijngaard JPHM, Schulten H, van Horssen P, et al. Porcine coronary collateral formation in the absence of a pressure gradient of ischemic border zone. Am J Physiol. 2011;300:H1930-H1937.
27. Schaper W. Collateral circulation: Past and present. Basic Res Cardiol. 2009;104:5-21.
28. Van Royen N, Piek JJ, Buschmann I, et al. Stimulation of arteriogenesis: A new concept for the treatment of arterial occlusive disease. Cardiovasc Res. 2001;49:543-553. (Pubitemid 32146417)
29. Gorge G, Schmidt T, Ito BR, et al. Microvascular and collateral adaptation in swine hearts following progressive coronary artery stenosis. Basic Res Cardiol. 1989;84:524-535. (Pubitemid 19273638)
30. Probst P, Zangl W, Pachinger O. Relation of coronary arterial occlusion pressure during percutaneous transluminal coronary angioplasty to presence of collaterals. Am J Cardiol. 1985;55:1264-1269. (Pubitemid 15035184)
31. Piek JJ, van Liebergen RA, Koch KT, et al. Comparison of collateral vascular responses in the donor and recipient coronary artery during transient coronary occlusion by intracoronary blood flow velocity analysis in patients. J Am Coll Cardiol. 1997;29:1528-1535. (Pubitemid 27272446)
32. Symons JD, Pitsillides KF, Longhurst JC. Chronic reduction of myocardial ischemia does not attenuate coronary collateral development in miniswine. Circulation. 1992;86:660-671.
33. Deindl E, Fernandez B, Hofer IE, et al. Arteriogenesis, collateral blood vessels and their development. In: Rubanyi GM ed. Angiogenesis in Health and Disease. New York, NY: Marcel Dekker; 2000: 31-45.
34. Werner GS, Jandt E, Krack A, et al. Growth factors in the collateral circulation of chronic total coronary occlusion. Circulation. 2004;110: 1940-1945.
35. Fleisch M, Billinger M, Eberli FR, et al. Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1-to 3-vessel coronary artery disease. Circulation. 1999; 100:1945-1950. (Pubitemid 29529285)
36. Lambiase PD, Edwards RJ, Anthopoulos P, et al. Circulating humoral factors and endothelial progenitor cells in patients with differing coronary collateral support. Circulation. 2004;109:2986-2992. (Pubitemid 38808321)
37. Murakami M, Nguyen LT, Hatanaka K, et al. FGF-dependent stimulation of VEGF receptor 2 expression in mice. J Clin Invest. 2011;121:2668-2678.
38. Nissen LJ, Cao R, Hedlund EM, et al. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest. 2007;117:2766-2777. (Pubitemid 47529608)
39. Onimaru M, Yonemitsu Y, Tanii M, et al. Fibroblast growth factor-2 gene transfer can stimulate hepatocyte growth factor expression irrespective of hypoxia-mediated downregulation in ischemic limbs. Circ Res. 2002;91:923-930. (Pubitemid 35373592)
40. Fujii T, Yonemitsu Y, Onimaru M, et al. Nonendothelial mesenchymal cell-derived MCP-1 is required for FGF-2-mediated therapeutic neovascularization: Critical role of the inflammatory/arteriogenic pathway. Arterioscler Thromb Vasc Biol. 2006;26:2483-2489. (Pubitemid 44607469)
41. Wempe F, Lindner V, Augustin HG. Basic fibroblast growth factor (bFGF) regulates the expression of the C-C chemokine monocytechemoattractant protein-1 (MCP-1) in autocrine-activated endothelial cells. Arterioscler Thromb Vasc Biol. 1997;17:2471-2478. (Pubitemid 28015983)
42. Murakami M, Simons M. Fibroblast growth factor regulation of neovascularization. Curr Opin Hematol. 2008;15:215-220. (Pubitemid 351507574)
43. Pepper MS, Ferrara N, Orci L, et al. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun. 1992;189: 824-831. (Pubitemid 23032448)
44. Tille JC, Wood J, Mandriota SJ, et al. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF-and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro. J Pharmacol Exp Ther. 2001;299:1073-1085. (Pubitemid 33104979)
45. Deroanne CF, Hajitou A, Calberg-Bacq C-M, et al. Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine upregulation of vascular endothelial growth factor expression. Cancer Res. 1997;57:5590-5597. (Pubitemid 28006769)
46. Masaki I, Yonemitsu Y, Yamashita A, et al. Angiogenic gene therapy for experimental critical limb ischemia: Acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circ Res. 2002;90:966-973. (Pubitemid 34633862)
47. Rissanen TT, Markkanen JE, Arve K, et al. Fibroblast growth factor 4 induces vascular permeability, angiogenesis and arteriogenesis in a rabbit hindlimb ischemia model. FASEB J. 2000;17:100-112.
48. Wolf A, O'Clair B, Groppi V, et al. Pharmacologic characterization of a kinetic in vitro human co-culture angiogenesis model using clinically relevant compounds. J Biomol Screen. 2013;18:1234-1245.
49. Bishop ET, Bell GT, Bloor S, et al. An in vitro model of angiogenesis: Basic features. Angiogenesis. 1999;3:335-344. (Pubitemid 129643976)
50. Donovan D, Brown NJ, Bishop ET, et al. Comparison of three in vitro human "angiogenesis" assays with capillaries formed in vivo. Angiogenesis. 2001;4:113-121. (Pubitemid 34032697)
51. Mandriota SJ, Pepper MS. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J Cell Sci. 1997;110:2293-2302. (Pubitemid 27448373)
52. Semenza GL. Regulation of tissue perfusion in mammals by hypoxiainducible factor 1. Exp Physiol. 2007;92:988-991. (Pubitemid 47568844)
53. Laham RJ, Rezae M, Post M, et al. Intracoronary and intravenous administration of basic fibroblast growth factor: Myocardial and tissue distribution. Drug Metab Dispos. 1999;27:821-826. (Pubitemid 29297781)
54. Henry TD, Annex BH, McKendall GR, et al. The VIVA trial. Circulation. 2003;107:1359-1365.
55. Simons M, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2 (FIRST trial). Circulation. 2002;105:788-793. (Pubitemid 34174916)
56. Giordano FJ, Ping PP, McKirnan MD, et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med. 1996;2:534-539. (Pubitemid 26151517)
57. Lyon AR, Sato M, Hajjar RJ, et al. Gene therapy: Targeting the myocardium. Heart. 2008;94:89-99.
58. Tsurumi Y, Kearney M, Chen D, et al. Treatment of acute limb ischemia by intramuscular injection of vascular endothelial growth factor gene. Circulation. 1997;96:II-382-II-388. (Pubitemid 27500061)
59. Prasad KM, Xu Y, Yang Z, et al. Robust cardiomyocytespecific gene expression following systemic injection of AAV: In vivo gene delivery follows a Poisson distribution. Gene Ther. 2011;18:43-52.
60. Tafuro S, Ayuso E, Zacchigna S, et al. Inducible adeno-associated virus vectors promote functional angiogenesis in adult organisms via regulated vascular endothelial growth factor expression. Cardiovasc Res. 2009;83: 663-671.
61. Roth DA, McKirnan MD, Canestrelli I, et al. Intracoronary delivery of an adenovirus encoding fibroblast growth factor-4 in myocardial ischemia: Effect of serum antibodies and previous exposure to adenovirus. Hum Gene Ther. 2006;17:1-9.
62. Henry TD, Grines CL, Watkins MW, et al. Effects of Ad5FGF-4 in patients with angina: An analysis of pooled data from AGENT-3 and AGENT-4 trials. J Am Coll Cardiol. 2007;50:1038-1046. (Pubitemid 47354223)
63. Liu Q, Muruve DA. Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther. 2003;10:935-940. (Pubitemid 36722427)
64. Shi W, Schmarkey S, Jiang R, et al. Ischemia-reperfusion increases transfection efficiency of intracoronary adenovirus type 5 in pig heart in situ. Hum Gene Ther Methods. 2012;23:1-9.
65. Sasano T, Kikuchi K, McDonald AD, et al. Targeted high efficiency, homogenous myocardial gene transfer. J Mol Cell Cardiol. 2007;42:954-961. (Pubitemid 46678029)
66. Boekstegers P, von Degenfeld G, Giehrl W, et al. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins. Gene Ther. 2000;7:232-240. (Pubitemid 30113772)
67. Lyons M, Onion D, Green NK, et al. Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol Ther. 2006; 14:118-128. (Pubitemid 44191831)
68. Carlisle RC, Di Y, Cerny AM, et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood. 2009;113:1909-1918.
69. Greig JA, Buckley SM, Waddington SN, et al. Influence of coagulation factor X on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors. Mol Ther. 2009;17:1683-1691.
70. Donahue JK, Kikkawa K, Johns D, et al. Ultrarapid, highly efficient viral gene transfer to the heart. Proc Natl Acad Sci U.S.A. 1997;94:4664-4668. (Pubitemid 27194300)
71. Logeart D, Hatem S, Rucker-Martin C, et al. Highly efficient adenovirusmediated gene transfer to cardiac myocytes after single-pass coronary delivery. Hum Gene Ther. 2000;11:1015-1022. (Pubitemid 30250118)
72. Fechner H, Noutsias M, Tschoepe C, et al. Induction of Coxsackieadenovirus receptor expression during myocardial tissue formation and remodeling. Circulation. 2003;107:876-882.
73. Emani S, Shah A, Bowman M, et al. Catheter-based intracoronary myocardial gene delivery: Importance of intraluminal seal and infusion flow rate. Mol Ther. 2003;8:306-313. (Pubitemid 37062840)
74. Hayase M, del Monte F, Kawase Y, et al. Catheter-based antegrade intracoronary viral gene delivery with coronary venous blockade. Am J Physiol Heart Circ Physiol. 2005;288:H2995-H3000. (Pubitemid 40720685)
75. Roth D, Lai N, Gao M, et al. Nitroprusside increases gene transfer associated with intracoronary delivery of adenovirus. Hum Gene Ther. 2004;15:989-994. (Pubitemid 39372575)
76. Logeart D, Hatem S, Hermburger M, et al. How to optimize in vivo gene transfer to cardiac myocytes: Mechanical or pharmacological procedures? Hum Gene Ther. 2001;12:1601-1610. (Pubitemid 32911731)
77. Yap J, Pellegrini C, O'Brien T, et al. Conditions of vector delivery improve efficiency of adenoviral-mediated gene transfer to the transplanted heart. Eur J Cardiothorac Surg. 2001;19:702-707. (Pubitemid 32416624)
78. Harris TR, Overholser KA, Collins JC. Tracer exchange in the normal and ischemic myocardium. Fed Proc. 1984;43:164-170. (Pubitemid 14185132)
79. Simons M, Bonow RO, Chronos NA, et al. Clinical trials in coronary angiogenesis: Issues, problems, consensus. An expert panel summary. Circulation. 2000;102:e73-e86.
80. Rana JS, Mannam A, Donnell-Fink L, et al. Longevity of the placebo effect in the therapeutic angiogenesis and laser myocardial revascularization trials in patients with coronary heart disease. Am J Cardiol. 2005; 95:1456-1459. (Pubitemid 40824767)
81. Seiler C, Fleisch M, Garachemani A, et al. Coronary collateral quantitation in patients with coronary artery disease using intravascular flow velocity or pressure measurements. J Am Coll Cardiol. 1998;32:1272-1279. (Pubitemid 28522383)
82. Seiler C, Billinger M, Fleisch M, et al. Washout collaterometry: A new method of assessing collaterals using angiographic contrast clearance during coronary occlusion. Heart. 2001;86:540-546. 89:1530-1538. (Pubitemid 32999866)
83. Seiler C. Assessment and impact of the human coronary collateral circulation on myocardial ischemia and outcome. Circ Cardiovasc Interv. 2013;6:719-728.
84. Hachamovitch R, Hayes SW, Friedman JD, et al. A prognostic score for prediction of cardiac mortality risk after adenosine stress myocardial perfusion scintigraphy. J Am Coll Cardiol. 2005;45:722-729. (Pubitemid 40278970)
85. Bolten HJ, van der Sijde JN, Ruitinga PR, et al. Long-term prognostic value of exercise technetium-99m tetrofosmin myocardial perfusion single-photon emission computed tomography. J Nucl Cardiol. 2012; 19:907-913.
86. Grines CL, Watkins MW, Mahmarian JJ, et al. A randomized, doubleblind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina (AGENT-2). J Am Coll Cardiol. 2003;42:1339-1347. (Pubitemid 37267270)
87. Schwarz ER, Schoendube FA, Kostin S, et al. Prolonged myocardial hibernation exacerbates cardiomyocyte degeneration and impairs recovery of function after revascularization. J Am Coll Cardiol. 1998;31: 1018-1026. (Pubitemid 28212501)
88. Chilian WM, Penn MS, Pung YF, et al. Coronary collateral growth-back to the future. J Mol Cell Cardiol. 2012;52:905-911.
89. Boodhwani M, Sellke FW. Therapeutic angiogenesis in diabetes and hypercholesterolemia: Influence of oxidative stress. Antioxid Redox Signal. 2009;11:1945-1959.
90. Ma C, Wang Q, Man Y, et al. Cardiovascular medications in angiogenesis-how to avoid the sting in the tail. Int J Cancer. 2012;131:1249-1259.
91. Gao MH, Lai NC, Hammond HK. Signal peptide increases the efficacy of angiogenic gene transfer for treatment of myocardial ischemia. Hum Gene Ther. 2005;16:1058-1064. (Pubitemid 41324565)